Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

por Xie, Xiao-Hong, Wang, Fei, Lin, Xin-Qing, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ouyang, Ming, Zhou, Cheng-Zhi
Publicado 2020

Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

por Xie, Xiao-Hong, Deng, Hai-Yi, Lin, Xin-Qing, Wu, Jian-Hui, Liu, Ming, Xie, Zhan-Hong, Qin, Yin-Yin, Zhou, Cheng-Zhi
Publicado 2021

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer

por Xie, Xiao-Hong, Zhan, Ze-Jiang, Qin, Yin-Yin, Jiang, Ju-Hong, Yin, Wei-Qiang, Zheng, Rong-Hui, Li, Shi-Yue, Zhou, Cheng-Zhi
Publicado 2021

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report

por Xie, Xiao-Hong, Shen, Pan-Xiao, Wu, Jian-Hui, Qiu, Gui-Huan, Lin, Xin-Qing, Xie, Zhan-Hong, Qin, Yin-Yin, Zheng, Bin, Liu, Ming, Zhou, Cheng-Zhi
Publicado 2023

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma

por Xie, Xiao-Hong, Wang, Li-Qiang, Qin, Yin-Yin, Lin, Xin-Qing, Xie, Zhan-Hong, Liu, Ming, Zhang, Jie-Xia, Ouyang, Ming, Liu, Jun, Gu, Ying-Ying, Li, Shi-Yue, Zhou, Cheng-Zhi
Publicado 2020